Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-201 in Healthy Participants
NCT07219368Phase 1Recruiting
- Start
- Oct 2025
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MT-201 in ulcerative colitis (UC), Crohn's disease and inflammatory bowel disease (IBD) (4 arms). Primary endpoint: Number of Participants with non-SAEs and SAEs at 40 weeks. Started Oct 2025; status: recruiting.
02
Drugs
MT-201
03
Conditions
ulcerative colitis (UC)Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07219368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219368.